ArticleLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society2009
Recurrent disease following liver transplantation for nonalcoholic steatohepatitis cirrhosis.
Article in Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Oral Semaglutide on Liver Fat and Body Composition in Liver Transplant Recipients With Diabetes Mellitus: Sema-Lit
Effect of Bempedoic Acid on Liver Fat in Individuals With Nonalcoholic Fatty Liver Disease and Type 2 Diabetes: Randomized Controlled Trial
Who cites it
43 citing papers in PubMed, 132 citations in OpenAlex.
- Liver transplantation in the era of obesity: A metabolic public health crisis meets a surgical frontier.Metabolism open · 2025Review
- Post-liver transplant mortality in Canada: A retrospective analysis and quality assurance study in British Columbia.Canadian liver journal · 2025Article
- Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD) after Liver Transplantation: A Narrative Review of an Emerging Issue.Journal of clinical medicine · 2024Review
- De Novo Metabolic Syndrome 1 Year after Liver Transplantation and Its Association with Mid- and Long-Term Morbidity and Mortality in Liver Recipients.Journal of clinical medicine · 2024Article
- Biguanides and glucagon like peptide 1 receptor agonists in the amelioration of post liver transplant weight gain; a scoping review of the mechanism of action, safety and efficacy.Gastroenterology and hepatology from bed to bench · 2024Article
- A Comprehensive Review of Liver Allograft Fibrosis and Steatosis: From Cause to Diagnosis.Transplantation direct · 2023Review
- Non-Invasive Measurement of Hepatic Fibrosis by Transient Elastography: A Narrative Review.Viruses · 2023Review
- Most Cases of Cryptogenic Cirrhosis May Be Nonobese Nonalcoholic Steatohepatitis - Risk Factors of Liver Steatosis After Liver Transplantation for Cryptogenic Cirrhosis: A Retrospective Study.Internal medicine (Tokyo, Japan) · 2023Article
- Inevitability of disease recurrence after liver transplantation for NAFLD cirrhosis.JHEP reports : innovation in hepatology · 2023Article
- Predictors of patient survival following liver transplant in non-alcoholic steatohepatitis: A systematic review and meta-analysis.EClinicalMedicine · 2022Article
- Evaluation of Magnetic Resonance Elastography and Transient Elastography for Liver Fibrosis and Steatosis Assessments in the Liver Transplant Setting.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2022Article
- Review
- Utility of Metabolomic Biomarkers to Identify Nonalcoholic Fatty Liver Disease in Liver Transplant Recipients.Transplantation direct · 2021Article
- Nonalcoholic Fatty Liver Disease after Liver Transplant.Journal of clinical and translational hepatology · 2021Review
- Medical management of metabolic and cardiovascular complications after liver transplantation.World journal of gastroenterology · 2020Review
- Non-alcoholic Fatty Liver Disease: Growing Burden, Adverse Outcomes and Associations.Journal of clinical and translational hepatology · 2020Review
- Nonalcoholic steatohepatitis recurrence after liver transplant.Translational gastroenterology and hepatology · 2020Review
- Approach to prevention of non-alcoholic fatty liver disease after liver transplantation.Translational gastroenterology and hepatology · 2020Review
- Hepatocellular carcinoma and metabolic syndrome: The times are changing and so should we.World journal of gastroenterology · 2019Article
- Incidence of Recurrent NASH-Related Allograft Cirrhosis.Digestive diseases and sciences · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recurrence of the original disease following liver transplantation is not uncommon and can lead to graft failure. There are limited data on recurrent fatty liver disease following liver transplantation. The aim of this study was to determine the incidence of recurrent fatty liver disease in patients with biopsy-proven nonalcoholic steatohepatitis, its effect on survival, and whether there are any predictive factors for recurrence. We analyzed patients undergoing liver transplantation for nonalcoholic steatohepatitis cirrhosis from 1997 to 2008 at a single center. Patients undergoing transplantation for cholestatic disease, alcohol, hepatitis C, or cryptogenic cirrhosis were controls. Ninety-eight patients underwent transplantation for nonalcoholic steatohepatitis cirrhosis. Recurrent fatty liver disease was seen in 70%, 25% had recurrent nonalcoholic steatohepatitis, and 18% had stage II/IV or greater fibrosis at a mean of 18 months. No patients with recurrent nonalcoholic steatohepatitis developed graft failure or required retransplantation at a follow-up of 3 years. No recipient or donor factors were associated with disease recurrence, although patients with recurrent nonalcoholic steatohepatitis had a higher incidence of diabetes, weight gain, and dyslipidemia at the time of diagnosis of recurrence. One-third of patients with recurrent nonalcoholic steatohepatitis had normal liver enzymes at the time of diagnosis post-transplantation. In conclusion, recurrent fatty liver disease is common following liver transplantation for nonalcoholic steatohepatitis cirrhosis but does not lead to early allograft failure. Recurrent nonalcoholic steatohepatitis can occur despite normal liver enzymes, and features of metabolic syndrome are associated with disease recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.